ANNEXA-4: Andexanet Reverses Factor Xa Inhibitors Amid Thrombotic Risk

This single-arm cohort defines the hemostatic and safety profile of andexanet alfa in factor Xa inhibitor-associated major bleeding, the dataset that underpinned its accelerated FDA approval.

andexanet alfaapixabanrivaroxabanedoxabanenoxaparinfactor Xa inhibitorsreversal agentsmajor bleedingintracranial hemorrhageanticoagulationcohort studyANNEXA-4 Cardiology / Anticoagulation

Background Information

Andexanet alfa reduces factor Xa activity by 92% in bleeding emergencies.

Major bleeding is a critical concern for patients using factor Xa inhibitors, and andexanet alfa offers a potential reversal option. Andexanet alfa reduced anti-factor Xa activity by 92% in patients on apixaban and rivaroxaban, achieving good or excellent hemostatic efficacy in 82% of cases. While andexanet effectively reduced factor Xa inhibitor activity and improved hemostasis, the associated thrombotic events and mortality highlight the need for careful patient monitoring. Andexanet alfa rapidly reverses factor Xa inhibitors, improving bleeding control in most cases but requires vigilant monitoring for thrombotic risks.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr, ANNEXA-4 Investigators

Citation: Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. The New England journal of medicine. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →